These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24111526)

  • 21. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
    Grant D; Johnsen H; Juelsrud A; Løvhaug D
    Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.
    Thomsen HS; Morcos SK; Almén T; Bellin MF; Bertolotto M; Bongartz G; Clement O; Leander P; Heinz-Peer G; Reimer P; Stacul F; van der Molen A; Webb JA;
    Eur Radiol; 2013 Feb; 23(2):307-18. PubMed ID: 22865271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic systemic fibrosis: histology and gadolinium detection.
    Thakral C; Abraham JL
    Radiol Clin North Am; 2009 Sep; 47(5):841-53, vi-vii. PubMed ID: 19744599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.
    Drel VR; Tan C; Barnes JL; Gorin Y; Lee DY; Wagner B
    FASEB J; 2016 Sep; 30(9):3026-38. PubMed ID: 27221979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadolinium contrast agent associated stimulation of human fibroblast collagen production.
    MacNeil S; Bains S; Johnson C; Idée JM; Factor C; Jestin G; Fretellier N; Morcos SK
    Invest Radiol; 2011 Nov; 46(11):711-7. PubMed ID: 21826007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nephrogenic systemic fibrosis--new clinical entity].
    Prvulović M
    Med Pregl; 2008; 61(9-10):439-41. PubMed ID: 19203058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadolinium-Induced Fibrosis.
    Todd DJ; Kay J
    Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
    Semelka RC; Prybylski JP; Ramalho M
    Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
    Jalandhara N; Arora R; Batuman V
    Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
    [No Abstract]   [Full Text] [Related]  

  • 34. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
    Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
    J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure.
    Schäd SG; Heitland P; Kühn-Velten WN; Gross GE; Jonas L
    J Cutan Pathol; 2013 Nov; 40(11):935-44. PubMed ID: 24102613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.